Innovotech Inc. Receives US$402,926 Following Exit from its Position in a Canadian Private Company

(TheNewswire)

Edmonton, Alberta – TheNewswire - July 8, 2025– Innovotech Inc. (TSX-V: IOT)(“Innovotech”) has received US$402,926 (approximately CA$550,562)following the sale of its 120,000 shares in a privately-held Canadiancompany effective July 1, 2025 with proceeds received July 7 at closeof business. The shares were acquired in February 2021 as theconsequence of a CA$150,000 convertible debenture that Innovotechinvestor Lonsdale Capital Corporation ("Lonsdale") assignedto Innovotech in exchange for 625,000 common shares in Innovotech at adeemed price of $0.24 each. A further US$33,339 is held back forworking capital adjustments and indemnity and a portion of this may berealized over the subsequent 18 months.

“The proceeds provide capital to continue executingon our plans, investing in profitable revenue growth and developinghigh value technologies.  We congratulate the teams involved in thetransaction for their milestone achievement and our supporters atLonsdale for their visionary work in building healthy businesses likeours.” said Craig Milne, Innovotech CEO.

About Innovotech:

Innovotech Inc.is a diversified Canadian technology company with business operationsin a growing portfolio of specialized laboratory services,biotechnology businesses, and proprietary intellectual property.Innovotech Inc. manages several subsidiary companies.  InnovotechLabs Corporation is a contract research organization that owns andprovides proprietary devices for antimicrobial testing in multipleapplications and commercializes antimicrobial silver solutions. Learnmore at www.innovotech.ca . Keystone Labs Inc. is a DEL-accredited labserving the Canadian pharmaceutical industry and industrial markets.Learn more at www.keystonelabs.ca. Innovotech Inc. owns a 60% stake inNouLifeSciences Inc., a company holding intellectual property relatedto antioxidant molecules with potential applications in cosmetics andvarious medical conditions including neuropathies.

Craig Milne, CEO Innovotech Inc.

+1-604-239-1819        craig.milne@innovotech.ca

This documentmay contain forward-looking statements that are predictive in natureand subject to risks and uncertainties that cannot be predicted orquantified; consequently, actual results may differ materially frompast results and those expressed or implied by any forward-lookingstatements. Factors that could cause or contribute to such risks oruncertainties include, but are not limited to: the regulatoryenvironment including the difficulty of predicting regulatoryoutcomes; changes in the value of the Canadian dollar; the Company’sreliance on a small number of customers including governmentorganizations; fluctuations in operating results; government policiesor actions; progress and cost of clinical trials; reliance on keystrategic relationships; uncertainty related to intellectual propertyprotection and potential costs associated with its defense; theCompany’s exposure to lawsuits and other matters beyond the controlof management. Should known or unknown risks or uncertaintiesmaterialize, or should management’s assumptions prove inaccurate,actual results could vary materially from those anticipated. TheCompany undertakes no obligation to publicly make or update anyforward- looking statements, except as required by applicable law.

Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.

###

Copyright (c) 2025 TheNewswire - All rights reserved.